Diabetes, Vol 44, Issue 12 1355-1361, Copyright © 1995 by American Diabetes Association

ARTICLES

Clinical trials of diabetic neuropathy: past, present, and future

MA Pfeifer and MP Schumer
Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield 62794-1619, USA.

This article reviews current knowledge of the etiology of diabetic neuropathy and the outcomes and limitations of previous trials and discusses future directions for the investigation of its prevention and treatment. Proposed mechanisms for the development of diabetic neuropathy have been widely studied. It has been shown that there is improvement of nerve function associated with some short-term clinical trials of treatments that address a number of possible etiologic pathways. Improvement of morphometry has also been demonstrated in some short-term clinical trials. However, with the exception of the Diabetes Control and Complications Trial (DCCT), long-term trials with adequate statistical power to evaluate clinical outcome endpoints have not been conducted. The changes in nerve function are similar in most of the clinical trials. For instance, in four clinical trials directed at separate mechanisms (improved glucose control, high myo-inositol diet, therapy with an aldose reductase inhibitor, and therapy with supplementary gamma-linolenic acid), a similar improvement in peroneal motor velocity of 1-2 m/s is observed. This implies that each of the proposed mechanisms contributes equally to the development of neuropathy or that there is some redundancy to their mechanisms. In addition to an etiologic approach, nonspecific neural stimulants, such as gangliosides and nerve growth factors, have also been investigated for the treatment of diabetic neuropathy.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Selvarajah, I. D. Wilkinson, C. J. Emery, N. D. Harris, P. J. Shaw, D. R. Witte, P. D. Griffiths, and S. Tesfaye Early Involvement of the Spinal Cord in Diabetic Peripheral Neuropathy Diabetes Care, December 1, 2006; 29(12): 2664 - 2669. [Abstract] [Full Text] [PDF]

				V. Bril, R. A. Buchanan, and the AS-3201 Study Group Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy Diabetes Care, October 1, 2004; 27(10): 2369 - 2375. [Abstract] [Full Text] [PDF]

				M. Polydefkis, P. Hauer, S. Sheth, M. Sirdofsky, J. W. Griffin, and J. C. McArthur The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy Brain, July 1, 2004; 127(7): 1606 - 1615. [Abstract] [Full Text] [PDF]

				V. Bril, Y. Ono, and R. A. Buchanan Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy Diabetes Care, May 1, 2004; 27(5): 1160 - 1163. [Abstract] [Full Text] [PDF]

				M. Polydefkis, J. W. Griffin, and J. McArthur New Insights Into Diabetic Polyneuropathy JAMA, September 10, 2003; 290(10): 1371 - 1376. [Abstract] [Full Text] [PDF]

				A. I. Vinik, R. E. Maser, B. D. Mitchell, and R. Freeman Diabetic Autonomic Neuropathy Diabetes Care, May 1, 2003; 26(5): 1553 - 1579. [Abstract] [Full Text] [PDF]

				S. M. Silver, B. M. Schroeder, and R. H. Sterns Brain Uptake of Myoinositol after Exogenous Administration J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1255 - 1260. [Abstract] [Full Text] [PDF]

				A. G. Smith, P. Ramachandran, S. Tripp, and J. R. Singleton Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy Neurology, November 13, 2001; 57(9): 1701 - 1704. [Abstract] [Full Text] [PDF]

				M. A. Barber, J. Conolley, C. M. Spaulding, and A. L. Dellon Evaluation of Pressure Threshold Prior to Foot Ulceration: One- versus Two-Point Static Touch J Am Podiatr Med Assoc, November 1, 2001; 91(10): 508 - 514. [Abstract] [Full Text] [PDF]

				E. Akarsu, I. Pirim, I. Çapoglu, O. Deniz, G. Akçay, and N. Ünüvar Relationship Between Electroneurographic Changes and Serum Ubiquitin Levels in Patients With Type 2 Diabetes Diabetes Care, January 1, 2001; 24(1): 100 - 103. [Abstract] [Full Text]